Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
Hematological Oncology · 2026-03 · 44 (2)
DOI: 10.1002/hon.70178 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 25.03.2026. Verfasst von Paola Guglielmelli und 55 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University …. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Farma S.p.A, Milano, Italy.
Abstract (Originalsprache)
Ruxolitinib (RUX), a JAK1/2 inhibitor, demonstrated treatment benefits for myelofibrosis (MF) in intermediate‐1 (Int‐1)–risk patients with a significant disease burden; however, the evidence is scarce. This interim analysis investigated the efficacy and safety of ruxolitinib in patients with Int‐1‐risk MF. ROMEI, a multicenter, observational, prospective study, enrolled 508 adult patients with MF receiving ruxolitinib according to approved indications. The present interim analysis was focused on 107 eligible patients in the Int‐1‐risk group. Primary endpoints included changes in symptoms response and health‐related quality of life scores. Secondary endpoints included spleen response evaluation, overall survival, and safety including dosing pattern and dose interruptions. Among the 107 Int‐1‐risk patients with a median age of 63 years, 65.5% were highly symptomatic (total symptoms score: ≥ 20), while the spleen was palpable at ≥ 5 cm and ≥ 10 cm in 74% and 27% of patients, respectively, with baseline EuroQol visual analogue scale (EQ‐VAS) score of 65.1 ± 19.4. After RUX treatment, 42.1% and 43.9% of patients demonstrated a symptom response at 24 and 48 weeks, while 38.9% and 46.8% showed a spleen response at 24 and 48 weeks, respectively. EQ‐VAS increased to 71.8 ± 16.3 at 24 weeks and 69.3 ± 19.2 at 48 weeks. Furthermore, 11.2% and 25.2% of patients reported temporary and permanent discontinuation, respectively with no new adverse events reported. The interim analysis showed that ruxolitinib provided clinical benefits, a manageable safety profile, and improved quality of life for Int‐1‐risk subgroup patients with frequent and sustained responses with acceptable toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.
- Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy.
- A. O. di Cosenza, Presidio Ospedaliero Annunziata, Cosenza, Italy.
- A. O. Policlinico Umberto I, Università La Sapienza, Roma, Italy.
- Hematology and Hematopoietic Stem Cell Transplantation Unit. PO "Vito Fazzi". ASL Lecce, Lecce, Italy.
- Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
ORCID-Profile: Paola Guglielmelli, Massimo Breccia, Paolo Sportoletti, Elisabetta Abruzzese, Alessandro Lucchesi, Massimiliano Bonifacio, Gianni Binotto, Mario Tiribelli, Francesco Passamonti, Francesca Palandri
Förderung
- Novartis Farma S.p.A, Milano, Italy
Zitieren
APA
Guglielmelli, P., Breccia, M., Mendicino, F., Martelli, M., Di Renzo, N., Palumbo, G. A., Crugnola, M., Musso, M., Sibilla, S., Sportoletti, P., Abruzzese, E., Impera, S., Malato, A., Siragusa, S., Selleri, C., Pane, F., Martino, B., Ricco, A., Gardellini, A., …, & Palandri, F. (2026). Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI). Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70178
Vancouver
Guglielmelli P, Breccia M, Mendicino F, Martelli M, Di Renzo N, Palumbo GA, et al. Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI). Hematological Oncology. 2026;44(2). doi:10.1002/hon.70178
BibTeX
@article{Guglielmelli2026,
author = {Guglielmelli, Paola and Breccia, Massimo and Mendicino, Francesco and Martelli, Maurizio and Di Renzo, Nicola and Palumbo, Giuseppe A and Crugnola, Monica and Musso, Maurizio and Sibilla, Silvia and Sportoletti, Paolo and Abruzzese, Elisabetta and Impera, Stefana and Malato, Alessandra and Siragusa, Sergio and Selleri, Carmine and Pane, Fabrizio and Martino, Bruno and Ricco, Alessandra and Gardellini, Angelo and Liberati, Anna Marina and Tafuri, Agostino and Langella, Maria and Brociner, Marco and Ditonno, Paolo and Pastore, Domenico and Mulas, Olga and Pocali, Barbara and De Gobbi, Marco and Morsia, Erika and Benevolo, Giulia and Elli, Elena Maria and De Stefano, Valerio and Falcone, Antonietta Pia and Vallisa, Daniele and Tomassetti, Simona and Lunghi, Francesca and Orofino, Nicola and Carli, Giuseppe and Urbano, Tiziana and Lucchesi, Alessandro and Brunoventre, Marta and Bonifacio, Massimiliano and Binotto, Gianni and Cavazzini, Francesco and Ranalli, Paola and Allegra, Alessandro and Anaclerico, Barbara and Mazzotta, Serena and Gherlinzoni, Filippo and Tiribelli, Mario and Castiglioni, Chiara and Landoni, Marina and Valsecchi, Diletta and Magnoli, Michela and Passamonti, Francesco and Palandri, Francesca},
title = {Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {2},
doi = {10.1002/hon.70178}
}
EUVIMED